NOXOPHARM-LIMITED
Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) announced an international patent application aimed at protecting the use of experimental anti-cancer drug, Veyonda® (idronoxil), in blocking the development of septic shock associated with infections such as COVID-19 and influenza viruses.
Overall, septic shock is believed responsible for an estimated 10 million global deaths per year, with an estimated three million additional deaths due to the current pandemic. So-called ‘long COVID’ symptoms (e.g., long-lasting fatigue, breathing problems, headaches), along with severe organ damage (e.g., limb amputation, diabetes, kidney, and heart failure) and death are all are outcomes associated with septic shock.
Veyonda is being developed as an anti-cancer drug based on immunostimulation and anti-inflammation functions. Its anti-inflammatory action stems from blocking of a signalling pathway called STING that normally serves as trigger for an inflammatory response to repair damaged tissue such as virally-infected lungs. In some individuals, the STING response is inappropriately excessive, pushing the individual over into septic shock. Veyonda is the first drug that blocks STING to be tested in septic shock, including in COVID-19 patients.
Graham Kelly , CEO of Noxopharm, said, “Globally, someone dies every three seconds from septic shock, the same rate as cancer. A cost-effective treatment for septic shock doubles the commercial opportunity for Veyonda.”
About Noxopharm
Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and septic shock.
Veyonda® is the Company’s first pipe-line drug candidate currently in Phase 2 clinical trialling. Veyonda® has two main drug actions – a moderating effect on the ceramide/sphingosine-1-phosphate balance and inhibition of STING signalling. Activity against the former target contributes to its dual-acting oncotoxic and immuno-oncology functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiotherapy and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, also contributing to an anti-cancer action, but also potentially blocking septic shock.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210414005036/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bridgepoint to Partner With ht.digital, the Leading Digital Asset Transparency Layer25.11.2025 09:00:00 CET | Press release
Bridgepoint to become majority shareholder in ht.digital, a London headquartered specialist provider of audit, accounting, assurance, operational and technology solutions to the digital asset ecosystem ht.digital has delivered organic revenue growth of c.100% over the last two years, scaling rapidly in a fast-growing market The partnership will accelerate ht.digital’s international expansion and continued investment in technology, talent and brand Bridgepoint, one of the world’s leading mid-market investors, today announced that it has agreed to acquire a majority stake in ht.digital, a leading, London-headquartered provider of digital asset assurance and technology solutions. The investment will be made by Bridgepoint Development Capital V – Bridgepoint’s lower middle-market fund focused on supporting fast-growing businesses across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251125907148/en/ Digital assets – incl
Thredd Signs Landmark Agreement to Enable Visa Cloud Connect Globally25.11.2025 09:00:00 CET | Press release
Agreement sets stage for strengthened global reach, scalability, and resilience for fintechs and banks worldwide Thredd, a leading next-generation global payments processor, today announced that it has signed an agreement to enable Visa Cloud Connect on a global scale. This milestone reflects Thredd’s continued investment in cloud-first infrastructure and reinforces its role as a global technology leader in payments processing. Visa Cloud Connect allows organisations to access VisaNet, Visa’s secure and powerful global payments network, through their own cloud-based infrastructure. Purpose-built for cloud-native clients, Visa Cloud Connect can help deliver increased flexibility, faster time to market, and seamless scalability across borders. Under the agreement, Thredd will connect across three global Visa Cloud Connect endpoints, committing to a full global rollout. Once live, this will eliminate the need for multiple regional integrations, helping our clients gain new geographies and
Allvue Expands European Footprint, Names KPMG Luxembourg as Core Implementation Partner25.11.2025 08:56:00 CET | Press release
The partnership offers managers seamless access to specialized local expertise and regulatory knowledge, ensuring accelerated confidence in adopting world-class, API-first technology, including Allvue’s AI tool, Andi. Allvue Systems, LLC (“Allvue”), a leading software technology provider for the private capital markets, today announced an expansion of its current presence in EMEA, naming KPMG Luxembourg as its core implementation partner for all client deliverables for Europe. The strategic collaboration is designed to meet the growing demand from global asset managers leveraging Luxembourg as the premier European fund domicile. By aligning Allvue’s world-class, unified technology platform and solutions with KPMG’s renowned local expertise in private assets, deep regional relationships, and plurilingual delivery capabilities, the partnership offers clients a faster, more effective path to technology adoption. “Our mission is to make private markets more transparent, efficient, and conn
Datassential Expands Global Menu Intelligence with Debut of Global Launches25.11.2025 08:30:00 CET | Press release
Datassential, the leading global food and beverage intelligence platform, announced the debut of Global Launches, an expanded menu–tracking solution offering a unified view of new menu items and limited-time offers (LTOs) across major international markets. Global Launches now tracks menu innovation across hundreds of restaurant chains in the European, Latin American, and Asia-Pacific markets. Building on the robust menu tracking already available in the U.S. and Canada, this expansion gives foodservice businesses a comprehensive view of new menu items and LTOs around the globe, providing unmatched visibility into how trends and flavors appear across worldwide markets and evolve to fit local tastes. “Innovation doesn’t happen in one market at a time — it’s global, constant, and increasingly fast,” said Jim Emling, CEO of Datassential. “Global Launches now offers our customers a single, trusted source to see what’s launching across the world, how concepts are localized, and where the ne
Friendly Fraud Expected to Increase by 25% Between Thanksgiving and Cyber Monday, Warns ACI Worldwide25.11.2025 08:00:00 CET | Press release
ACI’s Payments Intelligence approach offers merchants complete journey protection—stopping friendly fraud and chargeback abuse in real timeACI expects industry leading fraud approval rate of 98% during holiday season - outperforming market averages 'Friendly fraud’ is expected to increase by 25% between Thanksgiving and Cyber Monday, according to an analysis of billions of transactions of global eCommerce businesses by ACI Worldwide (NASDAQ: ACIW), an original innovator in global payments technology. ‘Friendly fraud’ or ‘return fraud’ occurs when legitimate customers dispute transactions post-purchase. Often mistaken for true fraud, these disputes are a growing industry challenge and cost retailers $103 billion in 2024 alone, according to a recent industry report. The average transaction value for a ‘friendly fraud’ item during this year’s holiday season is expected to reach $291, $52 higher than during the same period last year, representing a 21% YoY increase. “These numbers are stag
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom